Global Chemotherapy-induced Nausea and Vomiting Drugs Market 2020-2024: Anticipated to Grow by $525 Million - ResearchAndMarkets.com

The "Global Chemotherapy-induced Nausea and Vomiting Drugs Market 2020-2024" report has been added to ResearchAndMarkets.com's offering.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Tuesday, August 11, 2020
Information
Tags: 
Pharmaceutical, Health, Oncology, Other Health, Clinical medicine, Medicine, Medical specialties, Oncology, Antineoplastic drugs, Vomiting, Cancer treatments, Antiemetics, Chemotherapy-induced nausea and vomiting, Chemotherapy, Nausea, Dolasetron
⚠generated by AI ↴
Summary
Key Points: 
  • The "Global Chemotherapy-induced Nausea and Vomiting Drugs Market 2020-2024" report has been added to ResearchAndMarkets.com's offering.
  • The global chemotherapy-induced nausea and vomiting drugs market is poised to grow by $525 million during 2020-2024, progressing at a CAGR of 5% during the forecast period.
  • The study identifies the growing preference for chemotherapy drugs in developing countries as one of the prime reasons driving chemotherapy-induced nausea and vomiting drugs market growth during the next few years.
  • The chemotherapy-induced nausea and vomiting drugs market analysis includes therapy segment and geographic landscapes.


The "Global Chemotherapy-induced Nausea and Vomiting Drugs Market 2020-2024" report has been added to ResearchAndMarkets.com's offering.

The global chemotherapy-induced nausea and vomiting drugs market is poised to grow by $525 million during 2020-2024, progressing at a CAGR of 5% during the forecast period.

This report provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors. The report offers an up-to-date analysis regarding the current global market scenario, the latest trends and drivers, and the overall market environment.

The market is driven by the growing cancer population driving the market growth and approval of new drugs fuels the market growth. The study identifies the growing preference for chemotherapy drugs in developing countries as one of the prime reasons driving chemotherapy-induced nausea and vomiting drugs market growth during the next few years.

The chemotherapy-induced nausea and vomiting drugs market analysis includes therapy segment and geographic landscapes.

The chemotherapy-induced nausea and vomiting drugs market is segmented as below:

By Therapy

  • Serotonin receptor antagonists
  • NK1 receptor antagonists
  • Others

By Geographic Landscapes

  • North America
  • Europe
  • APAC
  • RoW

This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading chemotherapy-induced nausea and vomiting drugs market vendors that include:

  • Baxter International Inc.
  • Cipla Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Merck & Co. Inc.
  • Mylan N.V.
  • Novartis AG
  • Sanofi
  • Sun Pharmaceutical Industries Ltd.

Also, chemotherapy-induced nausea and vomiting drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

For more information about this report visit https://www.researchandmarkets.com/r/hvf1ag

Copyright: 
Copyright Business Wire 2020